Radioligand Therapy Continues to Show Promise for Metastatic CRPC
Radioligand therapy (RLT) with actinium-225 targeting prostate-specific membrane antigen (225Ac-PSMA) had a “substantial antitumor effect” in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC), a large, retrospective, multicenter study showed. Data on 488 men showed an overall survival (OS) of 15.5 months and median progression-free survival (PFS) of 7.9 months. A third of the patients had […]
HER3-Targeted Drug Active in Advanced/Metastatic Breast Cancer
An antibody-drug conjugate (ADC) targeting HER3 produced objective responses in as many as 43% of patients with advanced breast cancer, a prospective clinical trial showed. Responses to patritumab deruxtecan (HER3-DXd) occurred in the three major types of breast cancer, ranging from 22.6% in triple-negative breast cancer (TNBC) to 30.1% in hormone receptor (HR)-positive/HER2-negative breast cancer […]
CAR T-Cell Therapy Shows Promise in Advanced Kidney Cancer
ORLANDO — An off-the-shelf, allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD70 demonstrated antitumor activity in patients with advanced clear cell renal cell carcinoma (RCC), according to results from the phase I TRAVERSE trial. Three of 18 efficacy-evaluable patients (17%) responded to treatment with ALLO-316, and the disease control rate (DCR) reached 89%, reported […]
Robust PSA Drops With Radionuclide Therapy in Castration-Resistant Prostate Cancer
ORLANDO — An investigational radionuclide therapy targeting prostate-specific membrane antigen (PSMA) achieved biochemical responses in 70% of patients with castration-resistant prostate cancer (CRPC), and prostate-specific antigen (PSA) reductions in all but one patient, enrolled in a small preliminary clinical trial. Overall, 22 of 23 patients had some degree of PSA decline in response to fractionated […]
Anti-CD20 Agent Gains Approval for Multiple Sclerosis
Ublituximab (Briumvi), a monoclonal antibody targeting CD20, was approved for relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, TG Therapeutics announced. The FDA’s decision was based on two identical phase III trials of people with relapsing MS, ULTIMATE I and ULTIMATE II. At 96 weeks, ublituximab […]
‘Senolytic’ Therapy Shows Promise in Neovascular Eye Disease
NEW YORK CITY — An investigational drug targeting senescent cells achieved sustained improvement in visual acuity in patients with diabetic macular edema (DME) or neovascular age-related macular degeneration (AMD), a small pilot study showed. After single doses of UBX1325, four of eight evaluable patients with advanced DME had at least 10 letters of improvement in […]
Novel Drug Cuts Proteinuria in APOL1-Mediated Kidney Disease
An investigative treatment targeting APOL1 activity significantly improved proteinuria APOL1-mediated kidney disease (AMKD), a proof-of-concept phase IIa study found. In a single-arm, open-label study, treatment with oral VX-147 — a small molecule acting as an APOL1 function inhibitor — significantly reduced urine protein to creatinine ratio (UPCR) by 47.6% (95% CI -60 to -31.3%) by […]
House Lawmakers Eager to Boost Vaccine Uptake, Quash Hesitancy
Implementing so-called “regret lotteries,” launching school vaccination clinics, and targeting “microherds” were among the strategies proposed by expert witnesses to address vaccine hesitancy, during a hearing of the House Select Subcommittee on the Coronavirus Crisis on Thursday. “Nearly all of the more than 8,500 Americans who died from COVID-19 last month were unvaccinated,” said Chairman […]